ContactISSN:e-ISSN: 2757-976X
Author Sign-inReviewer Sign-inRegister
TürkçeEnglish
Home
About Journal
Copyright NoticeOpen Access PolicyAim and ScopePrinciples of ArbitrationReviewer and Editor GuideFee PolicyEthical Principles and Publication PolicyArchiving PolicyIndexing
Information For AuthorsEditorial BoardSend ArticleLatest IssueArchiveContact Us

Non-Alcoholic Fatty Liver Disease Rate İn Erzurum And Its Surroundings

Özkan Çinici,Muammer Altınkaynak,Neslihan Bayındır,Doğan Nasır Binici

  • Özkan Çinici: SBU Erzurum Tıp Fakültesi Erzurum Şehir Hastanesi
  • Muammer Altınkaynak: SBU Erzurum Şehir Hastanesi
  • Neslihan Bayındır: SBU Erzurum Şehir Hastanesi
  • Doğan Nasır Binici: SBÜ Erzurum Tıp Fakültesi Erzurum Şehir Hastanesi
  •  Year : 2025
  •  Vol : 5
  •  Issue : 1
  •  Page : 5-10
Objective: The frequency of nonalcoholic fatty liver disease ( NAFLD ) is not known clearly because there are not enough clinical studies in our country. The disease is a finding that may occur incidentally when an abdominal ultrasound is performed in patients who do not have any complaints or apply to the hospital for different clinical reasons. Studies have shown that at least 25 percent of American adults have fatty liver. Our aim is to detect the frequency of NAFLD in Erzurum and its surroundings and to determine the change in our region over a ten-year period. Methods: In this study, 60000 patients who were admitted to our hospital between 2009 and 2019 and underwent ultrasonography for any reason were examined retrospectively. Prevalence was analyzed according to ultrasound findings, age, gender and body mass index (BMI). Results: NAFLD was detected in 42.1 % of the patients who participated in the study. This rate was determined as 43 % for men and 41.6 % for women. The highest rate was seen in those over 60 years of age ( 43.8 % ), in male gender ( 43 % ), and in those with BMI >25 kg/m2 ( 45 % ). Multivariate analysis showed that male gender, serum alanine aminotransferase level, older age, BMI, type II diabetes, hypertension, and dyslipidemia were independent factors associated with NAFLD. Conclusion: NAFLD is a disease that affects nearly half of the people living in our region and is about to become a public health problem. All asymptomatic individuals who are overweight or obese and have risk factors should be investigated for NAFLD.
Cite this Article As : Çinici Ö, Altınkaynak M, Bayındır N, Binici DN. Erzurum ve Çevresinde Alkolsüz Yağlı Karaciğer Hastalık Oranı. Mev Med Sci. 2025; 5(1): 5-10

Conflict of interest : The authors declare that they have no conflict of interest.

This article is published under the CC BY-NC 4.0 license.
Mevlana Tıp Bilimleri
2025, Vol5, Issue1
E-ISSN: 2757-976X
Received : , Accepted : , Published Online :

References

  1. 1. Ludwig J, Viggiano TR, Mcgill DB, et al. Nonalcoholic steatohepatitis, Mayo Clinic experiences with a hitherto unnamed disease. In Mayo Clinic Proceedings, 1980; 55(7): 434-8.
  2. 2. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. American Journal of Physiology-Endocrinology and Metabolism, 2005; 288(2): 462-8.
  3. 3. Akif A. Non Alkolik Yağlı Karaciğer Hastalığında Güncel Medikal Tedavi. Kocatepe Tıp Dergisi, 2015; 16: 1.
  4. 4. Jansen PL. Nonalcoholic steatohepatitis. Neth J Med, 2004; 62(7): 217-24.
  5. 5. Falck Y, Younossi ZM, Marchesini G, et al. Clinical features and natural history of nonalcoholic steatosis syndromes. In Seminars in liver disease, 2001; 21(01): 17-26.
  6. 6. Ruhl CE, Everhart JE. Epidemiology of nonalcoholic fatty liver. Clinics in liver disease, 2004; 8: 501-19.
  7. 7. Day CP, James OF. Steatohepatitis: a tale of two “hits”?, Elsevier, 1998; 114(4): 842-5.
  8. 8. Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). International journal of molecular sciences, 2013; 14(10): 20704-28.
  9. 9. Lomonaco R, Chen J, Cusi K. An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Therapeutic advances in endocrinology and metabolism, 2011; 2: 211-25.
  10. 10. Saadeh S, Younossi ZM, Remer M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology, 2002; 123: 745-50.
  11. 11. Vuppalanchi R, Cummings OW, Saxena R, et al. Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis: a study of human liver samples. Journal of clinical gastroenterology, 2007; 41(2): 206-10.
  12. 12. Siegelman ES, Rosen MA. Imaging of hepatic steatosis. in Seminars in liver disease. Thieme Medical Publishers, Inc, 2001; 21(01): 71-80.
  13. 13. Joseph AE, Saverymuttu A, Al-Sam SH, et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clinical radiology, 1991; 43(1): 26-31.
  14. 14. Bydder GM, Kreel L, Chapman RW, et al. Accuracy of computed tomography in diagnosis of fatty liver. British Medical Journal, 1980; 281(6247): 1042.
  15. 15. Janiec DJ, Jacobson ER, Freeth A, et al. Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. Obes Surg., 2005; 15: 497-501
  16. 16. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology, 2005; 128: 1898-906.
  17. 17. Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management ogf non-alcoholic steatohepatitis. Clin Liver Dis., 2007; 11: 37-54.
  18. 18. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016; 64: 73-84
  19. 19. Sung KC, Wild SH, Byrne CD. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. J Hepatol, 2014; 60: 1040-5.
  20. 20. Chang Y, Jung HS, Cho J, et al. Metabolically healthy obesity and the development of nonalcoholic fatty liver disease. Am J Gastroenterol, 2016; 111: 1133-40
  21. 21. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol, 2015; 62(1): 47-64.
  22. 22. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis, 2009; 13: 511-31.
  23. 23. Koehler EM, Schouten JN, Hansen BE, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in the elderly: results from the Rotterdam study. J Hepatol, 2012; 57: 1305-11.
  24. 24. Fattahi MR, Niknam R, Safarpour A, et al. The prevalence of metabolic syndrome in non-alcoholic fatty liver disease; a population-based study. Middle East J Dig Dis, 2016; 8: 131-7.
  25. 25. Zelber S, Nitzan D, Halpern Z, et al. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int, 2006; 26: 856-63.
  26. 26. Celebi S, Ataseven H, Mengucuk E, et al. Epidemic features of nonalcoholic fatty liver in urban community of Elazıg. Akademik Gastroenteroloji Dergisi, 2006; 5: 41-6.
  27. 27. Kasapoglu B, Turkay C, Yalcin KS, et al. Low vitamin D levels are associated wıth increased risk for fat¬ty liver disease among non-obese adults. Clin Med, 2013; 13: 576-9.
  28. 28. Okur G, Karacaer Z. The prevalence of non-alcoholic fatty liver disease in healthy young persons. North Clin Istanb, 2016; 3: 111-7.
  29. 29. Kaya E, Yılmaz Y. Non-alcoholic fatty liver disease: A growing public health problem in Turkey. Turk J Gastroenterol, 2019; 30(10): 865-71.
  30. 30. Sezgin O, Akpinar H, Ozer B. Kapadokya Kohort Çalışması, Gastrointestinal hastalıkların ve Ultrasonografik Bulguların Görülme Sıklığı. 35. International Gastroenterology Congress; 2018 November 21-25; Antalya, Turkey. SS (Vol. 85).